|
|
|
| Study on the mechanism of Hirudo-Scolopendra couplet medicines in the treatment of diabetic erectile dysfunction based on network pharmacology#br# |
| WANG Xuyun1 HU Zhiwei2 JIANG Zikang3 HU Jintao4▲ |
1.Department of Andrology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China;
2.Department of Rehabilitation, Dalian Hospital of Traditional Chinese Medicine, Liaoning Province, Dalian 116013, China;
3.Department of Traditional Chinese Medicine, School of Medicine, Xiamen University, Fujian Province, Xiamen 361102, China;
4.Department of Pediatric, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100070, China |
|
|
|
Abstract Objective To explore the mechanism of Hirudo-Scolopendra couplet medicines in the treatment of diabetic erectile dysfunction (DED) by using network pharmacology method. Methods The relevant ingredients of Hirudo-Scolopendra couplet medicines were obtained by searching relevant literatures from January 1, 2017 to February 10, 2020 in CNKI. Swiss Target Prediction data platform was used to screen the main effective components and targets of Hirudo-Scolopendra couplet medicines; Cytoscape 3.8 was used to draw the drug-component-target network; OMIM and Drugbank dataBases were used to retrieve the related targets of diabetes mellitus (DM)-erectile dysfunction (ED); Venn diagram was used to obtain the common targets of Hirudo-Scolopendra couplet medicines, DM, and ED; protein-protein interaction network of components-disease common targets were constructed by using STRING platform; gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed by using Metascape database. Results A total of 47 active ingredients and 534 related targets were obtained from Hirudo-Scolopendra couplet medicines, DM and ED related targets were 736 and 743, respectively, and this couplet medicines had 32 targets for regulating DM and ED, and three core common targets were obtained by screening again; GO enrichment analysis showed that there were 14 biological processes and four molecular function. KEGG pathway enrichment analysis showed that there was a total of one core signaling pathway, which was the cancer pathway. Conclusion Hirudo-Scolopendra couplet medicines may treat DED by acting on AR, ESR1 through cholesterol, linolenic acid and other components, so as to restore erectile function.
|
|
|
|
|
|
[1] 盛文，吴松立，刘菡，等.糖尿病性勃起功能障碍的中医理论探析[J].中国性科学，2017，26（6）：89-91.
[2] 王旭昀，商建伟，盛文，等.糖尿病勃起功能障碍中医饮食治疗浅析[J].中国医药导报，2018，15（31）：124-126.
[3] 王旭昀，张宏，商建伟，等.补肾活血法治疗男科疾病浅谈[J].中国性科学，2018，27（8）：130-132.
[4] 汲丽丽，吕邵娃，杨志欣.蜈蚣化学成分与药理作用研究进展[J].特产研究，2020，42（4）：75-84.
[5] 李国强，李韵仪，李桃，等.水蛭的化学成分研究[J].天津中医药，2018，35（9）：703-705.
[6] 李园媛.水蛭提取液对视网膜母细胞瘤的抑制作用及相关分子机制研究[D].成都：成都中医药大学，2020.
[7] 王家兴，任桐.水蛭及其活性成分治疗脏器纤维化研究进展[J].辽宁中医杂志，2020，47（5）：213-216.
[8] 郭雪峰，侯德才，柳椰.基于网络药理学探讨水蛭防治股骨头坏死的作用机制[J].中华中医药学刊，2021，39（1）：235-237.
[9] 李宗国，时召平，张鹏飞.黄芪和水蛭有效成分对肾小球系膜增生的作用及其机制[J].承德医学院学报，2020，37（4）：275-280.
[10] 于永慧.心梗后纤维化心肌ECM蛋白表达谱构建及水蛭素的干预效应研究[D].北京：中国中医科学院，2019.
[11] 周绪云.一测多评法测定水蛭中尿嘧啶、次黄嘌呤、黄嘌呤和尿苷的含量[J].中国药品标准，2019，20（4）：339-345.
[12] 顾叶云，胡莹杰，徐蕾，等.黄芪、水蛭有效组分对经脂多糖诱导增生的大鼠肾小球系膜细胞IκB、NF-κB、PDGF-BB表达的影响[J].中华中医药杂志，2020，35（2）：866-868.
[13] 杨玄，环娟娟，沈婷婷，等.养殖宽体金线蛭营养成分分析[J].江苏农业科学，2020，48（8）：198-201.
[14] 顾念念，索亚然，乔艺涵，等.柱前衍生-HPLC法对水蛭的指纹图谱及其16种氨基酸含量测定研究[J].环球中医药，2020，13（4）：592-599.
[15] 张琪，朱叶华，文红梅，等.HPLC-PDA同时测定不同品种及产地蜈蚣中8种核苷类成分[J].中国实验方剂学杂志，2017，23（14）：57-61.
[16] 王进喜，杨天军，周曦曦，等.苗药爬岩蜈蚣化学成分定性研究[J].中国民族医药杂志，2017，23（6）：39-40.
[17] 刘春雨，曹广超，王彦多，等.中药蜈蚣研究进展[J].化工时刊，2017，31（7）：41-46.
[18] 吴福林，周柏松，董庆海，等.中药蜈蚣的研究进展[J].特产研究，2018，40（1）：69-76.
[19] 吴春红.少棘蜈蚣最细粉急性毒性和慢性毒性研究[D].泸州：西南医科大学，2018.
[20] 董青，郑敏惠.蜈蚣毒液的农药活性及其作为生物农药的潜力[J].湖北农业科学，2019，58（S2）：61-66.
[21] 张彬若，刘录，李晓红，等.彝药地蜈蚣中化学成分的分离及含量测定[J].中药材，2020，6（4）：917-921.
[22] 沈爽，焦连庆，张梦鹄，等.柱前衍生化RP-HPLC法测定蜈蚣中9种生物胺的含量[J].中药材，2020，9（8）：1939-1943.
[23] 李建，陈爽，王强，等.慢性前列腺炎患者实施水蛭蜈蚣栓加入微波治疗的效果[J].中国性科学，2018，27（9）：23-26.
[24] 李宪锐，商建伟，王景尚，等.李曰庆教授治疗特发性少弱精子症药对浅析[J].中国性科学，2020，13（7）：1257-1260.
[25] 戴其军，柯进，徐沛.三虫胶囊组成成分的药理分析[J].云南中医中药杂志，2019，40（9）：50-52. |
|
|
|
